Laboratoire des Pathog nes mergents (LPE) Fondation M rieux - - PDF document

Laboratoire des Pathogиnes Йmergents (LPE) Fondation Mйrieux

GABRIEL Network Meeting Presentation Session

Les Pensiиres, December 11th

Glбucia Paranhos-Baccalа, PhD, HDR Director

LPE Facilities

• located in Lyon at the Inserm building: 300 m2
• access to:

‐ P2 and P3 laboratories designed for molecular biology including Affymetrix station, cell culture, viral isolation, cloning and sequencing, … ‐ P4 Laboratory located in the same area; ‐ Technical platforms from the IFR 128 Biosciences: genetic analysis, in vivo screening, imagery and microscope, flux cytometry, proteins production and analysis, bioinformaticians, … http://www.ifr128.prd.fr/

• collaborate with:

‐ Academic scientists ‐ Armed forces Health Service ‐ Pediatricians, physicians, virologists, bacteriologists

Surveillance and Alert Prevention and Treatment Epidemiology

Emerging Pathogens Laboratory

Design of molecular tests for multi-pathogens detection to conduct applied research

GABRIEL Network

Patient

Positive diagnostic Public Health Negative diagnostic

(Clinical data associated)

Transfer / Training

LPE and GABRIEL network: How do we work ?

Pathogen Discovery Host- Pathogen

Identification

• f unknown

Pathogens

External collaborations

Hospitals, Academic Research Laboratories and Industries

LPE and Research Activities*

• Pulmonary syndrome

Pulmonary syndrome-

• based

based

• Acute Lower Respiratory Infections (ALRI):

Pneumonia and Bronchiolitis

• Influenza
• Tuberculosis drug resistance surveillance
• Pathogen Discovery

Pathogen Discovery

• Respiratory infections
• Encephalitis
• Hemorrhagic Fevers, BSL4

Hemorrhagic Fevers, BSL4

* Please visit LPE Poster numbers: 11, 12, 14, 17, 23, 24, 29 an * Please visit LPE Poster numbers: 11, 12, 14, 17, 23, 24, 29 and 30. d 30.

LPE and Main Research activities Acute Lower Respiratory Infections (ALRI)

• worldwide occurrence;
• high spread in poor communities;
• the second leading causes of death in low income countries;
• represent a major public health problem, especially for children.

Influenza

• every year in the United States, on average:
• 5% to 20% of the population gets the flu;
• more than 200,000 people are hospitalized from flu-related complications; and
• about 36,000 people die from flu-related causes.

Tuberculosis drug resistance surveillance

• more than 14 million of TB cases worldwide; and more than 8 million new

cases every year;

• the 500,000 estimated cases of multi-drug resistant TB (MDR-TB) need

characterization and surveillance; i t d t f d l i t i

LPE the main questions: Respiratory Infections

ALRI -

Bronchiolitis and Pneumonia Bronchiolitis and Pneumonia Identification Identification: : Which are the pathogens in the origin of these diseases?

• simultaneous molecular identification of more than

20 viruses, atypical bacteria and bacteria. Which are the severity criteria?

• identification of co-infections and host-markers

associated. How to manage the risk of new Influenza Pandemia?

• to molecular genotype and detect the mutations conferin

resistance to antiviral drugs.

*Grants: USB OPTIMUS Foundation (to be announced) and MINEFI (GAP Project).

LPE the main questions: TB

MDR-TB molecular detection tools and trends.

• Surveys
• Epidemiological trends
• Improvement on patient management

XDR-TB

• Complete genome sequencing to identify new genes confering

resistance

*Grants: CAMS and Mйrieux Alliance (to be announced).

MDR/XDR-TB -

LPE the main questions: Pathogen Discovery

Pathogen Discovery -

To identify new or mutants emerging pathogens in samples from children and adults suffering of respiratory and other diseases without pathogen association; Strengths:

• The BSL3 and BSL4 «Laboratoire P4 - Jean Mйrieux»

laboratories are a strong asset,

• Sophisticated technological platform (high throughput cloning

and sequencing).

*Grants: A platform in Lyon with academics and companies through a new call for grant of LyonBioPфle (to be done).

LPE the main questions: Host Markers

Correlation with inflammatory cytokines, CRP and PCT with bacteremic and non-bacteremic or viremic pulmonary syndromes in children and adults specimens. To predict: outcome, severity and mortality. To Identify and Characterize host markers such as immunomodulators associated with hemorrhagic fever viruses (P4 Laboratory).

Host-Pathogen Markers - The The LPE Team LPE Team

• Applied Research and Scientific Support;
• Technological Transfer and Support;
• Training of Laboratory Managers / Technicians.